Answer
Eculizumab may reduce rituximab’s expected pharmacodynamic effects through potential inhibition of rituximab’s complement-dependent cytotoxicity, although no interaction studies have been performed.
Sources for this answer
- Soliris 300 mg concentrate for solution for infusionAlexion Pharma UK Ltd · emc · SmPC §4.5 Interaction with other medicinal products · Version 29Document updated
Sources checked